Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05184335 | Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia | PHASE3 | RECRUITING | 690 | — | — | Jan 1, 2022 | Feb 1, 2025 | Dec 18, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| Brilaroxazine | DRUG | RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride. |
| Placebo | OTHER | RP5063 matching Placebo |